Betahistine and Weight- Related and Metabolic Measures in schizophrenic Patients Treated with Olanzapin or Risperidone

The Effect of Betahistine on Weight- related and Metabolic Measures in Patients with Schizophrenia Treated with Olanzapine and Risperidone

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191223045870N1

Enrollment

Registered

2020-03-13

Start date

2020-06-09

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: the intervention group received second generation of antipsychotics (Olanzapine or Risperidone) as a routine treatment and Betahistine (as an intervention), from 8

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Patient or Legal Guardian Informed Consent Have Schizophrenia Based on DSM5 18-59years old Treated With Olanzapine or Risperidone That It Dosen't Change During The Study Weight Gain At Least 7% Of Total Body Weight In The First Year of Treatment With Anti Psychotics Or In a Resent Year If The Patient Is Taking Medication For Hyperlipidemia or Hypertention or Tyroid Disorders The Dose of Medication Did not Changed During The Study The Patients Do not Have Another Medical or Psychiatric Disease Do not Use Substance (Except Nicotine)

Exclusion criteria

Exclusion criteria: Have Asthma Have Peptic Ulcer Have Pheochromocytoma Liver and Kidney Disfunction Treated with Other Weight Related Medications Like Sodium Valproarte or Weight loss or Appetite Suppressant Medications Have Allergy to Betahistine Pregnant or Lactating

Design outcomes

Primary

Measure	Time frame
Weight Related Measures(weight,waist and Hip circumfrence,BMI). Timepoint: At The Begining of the Study Then Every Month. Method of measurement: Weight measure with scales, Waist and Hip circumference measure with Meter.;Fasting blood sugar. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Laboratory Glucose kit.;Lipid profile include cholesterol and tri glyceride. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Laboratory cholestrol and triglycerid kits.;Thyroid stimulating hormone. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Enzyme linked immunosorbent test.	—

Measure

Time frame

Weight Related Measures(weight,waist and Hip circumfrence,BMI). Timepoint: At The Begining of the Study Then Every Month. Method of measurement: Weight measure with scales, Waist and Hip circumference measure with Meter.;Fasting blood sugar. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Laboratory Glucose kit.;Lipid profile include cholesterol and tri glyceride. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Laboratory cholestrol and triglycerid kits.;Thyroid stimulating hormone. Timepoint: At the Begining of The Study And After 12 weeks. Method of measurement: Enzyme linked immunosorbent test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNajme Abbasi Jannatabadi

Mashhad University of Medical Sciences

Najmeabbasi84@yahoo.com+98 51 3712 7017

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026